Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biogen Amevive NDA Filing For Psoriasis Expected In Second Half Of 2001

Executive Summary

Biogen plans to file an NDA for the T-cell modulator Amevive for psoriasis in the second half of 2001, VP-Medical Research Burt Adelman, MD, said during the company's first quarter conference call April 12.

You may also be interested in...



Genentech Considers Xanelim Chronic Psoriasis Therapy Indication

Genentech hopes to position Xanelim for use as a chronic therapy for moderate to severe plaque psoriasis based on six-month data.

Genentech Considers Xanelim Chronic Psoriasis Therapy Indication

Genentech hopes to position Xanelim for use as a chronic therapy for moderate to severe plaque psoriasis based on six-month data.

GlaxoSmithKline Is Mouthful But Still Hungry: Is Next Course Japanese?

GlaxoSmithKline's acquisition strategy will concentrate on medium-sized pharmaceutical and biotech companies with a pipeline, CEO J.P. Garnier told analysts during a Feb. 22 meeting in London.

UsernamePublicRestriction

Register

LL1132098

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel